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Summary
Treatment of female hypogonadotropic hypogo-
nadism is geared to mimic normal physiology, al-
lowing for age appropriate development, while pre-
venting complications secondary to sex hormone
deprivation. In this paper we review data concern-
ing efficacy and safety of sex hormone replace-
ment therapy at the various stages of female repro-
duction, taking into account safety profiles of dif-
ferent types of estrogen and progesterone formula-
tions, and their interactions with other components
of the pituitary substitutive therapy.
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Introduction
As with other deficiencies in hypothalamo-pituitary-tar-
get organ axes, treatment of female hypogonadotropic
hypogonadism is geared to mimic normal physiology, al-
lowing for age appropriate development, while prevent-
ing complications secondary to sex hormone depriva-
tion. That we do not fully achieve this goal is suggest-
ed by reports of excess mortality in patients with hy-
popituitarism (1), which is more pronounced in women
than in men (2).
In children, sex steroid hormone replacement is given
gradually to simulate normal pubertal development. In
adulthood, issues of fertility including induction of ovu-
lation, normal sexual functioning as well as achieve-
ment and maintenance of bone health should be ad-
dressed. In this paper we will review data concerning
efficacy and safety of sex hormone replacement thera-
py at the various stages of female reproduction, taking
into account safety profiles of different types of estro-
gen and progesterone formulations, and their interac-
tions with other components of the pituitary substitutive
therapy.
Puberty and adolescence
The goal of therapy is to simulate normal puberty, in-
cluding the development of secondary sex characteris-
tics, uterine and endometrial maturation and bone
mass accretion, while fulfilling the genetic potential for
height and allowing for psychosocial maturation at an
appropriate age. Unfortunately, evidence-based infor-
mation regarding the optimal treatment schedule for
children with hypogonadotropic hypogonadism is
sparse, and their clinical management relies on data
obtained mainly from studies in girls with Turner’s syn-
drome (3).  Regarding the timing of pubertal induction,
delaying estrogen therapy to optimize height potential
is no longer recommended, more emphasis being giv-
en to age appropriate pubertal maturation (4).The ini-
tial estrogen dose should be one tenth to one eight of
the adult replacement, followed by a gradual dose in-
crease over a period of 2-4 years (4). Progestins
should be added at least two years after estrogen initi-
ation, or if breakthrough bleeding occurs.
Oral estrogens, mostly conjugated estrogens in the US
and ethinyl estradiol or micronized estradiol in Europe
have been the predominant preparations used by pedi-
atric endocrinologists (3), although there seem to be a
trend to move to transdermal preparations in the last
decade. In the guidelines formulated by the Turner
Syndrome Study Group (4) there is no specific recom-
mendation as to the type of estrogen formulation to be
used, and dose equivalence is provided for conjugated
equine estrogens, ethynil estradiol and micronized
estradiol, but it is suggested that treatment regimens
using injectable or transdermal estradiol may be more
physiological.
Oral estrogen preparations may potentially have dele-
terious effects on maximal height attainment, as they
undergo first-pass metabolism in the liver leading to re-
duced IGF-1 generation, an effect not seen with phys-
iological doses of transdermal/parenteral  estradiol
preparations (5). This notion is supported by results of
a small study in which girls treated with very small dos-
es of parenteral depot estradiol from the age of 12
achieved significantly more linear growth in compari-
son with those treated with conjugated estrogens start-
ed at a similar age (6). Additional evidence comes from
Review
Hypogonadotropic hypogonadism in women: 
treatment options











Hypogonadotropic hypogonadism in women: treatment options
Reviews in Endocrinology and Metabolism 2013; 1 (2): 62-66 63
a prospective French registry study in which transder-
mal estradiol treatment was independently associated
with improved adult height (7). 
Evidence pointing to a possible superiority of the trans-
dermal route in attaining other endpoints of pubertal
development has been accumulating. A recent study
on estrogen replacement in pre-pubertal girls with
Turner syndrome showed that transdermal estradiol,
as compared with oral conjugated estrogens, resulted
in greater accrual of spine bone mineral content and
density, as well as greater increases in uterine length
and volume (8). The importance of achieving normal
uterine development cannot be overemphasized as it
may influence response rates to subsequent fertility
treatments. There seems to be a dissociation between
breast development and uterine growth in certain regi-
ments of pubertal induction. For example, only 50% of
girls with Turner syndrome with complete secondary
sexual development had a mature size and shaped
uterus when treated with ethinyl estradiol (9). Similarly,
patients with  hypopituitarism or hypogonadotropic hy-
pogonadism treated with a standard ethinyl estradiol
regimen for induction of puberty were also found to
have significantly smaller uterus length and uterus
cross-sectional area in comparison to controls (10). In
contrast, treatment with increasing doses of estradiol
gel resulted in normal uterine development in all pa-
tients (11). Consideration should also be given to the
dose of estradiol, as a positive correlation has been
found between postmenarcheal estrogen dose and
uterine length (12). In view of the accumulating evi-
dence in favor of transdermal estradiol for the purpose
of puberty induction, its use has significantly in-
creased, not only in patients with primary ovarian fail-
ure but also in those with hypogonadotropic hypogo-
nadism (13). 
Fertility
With the advent of ovulation induction with go-
nadotropins more than five decades ago, women with
hypopituitarism should expect near normal fecundity.
In contrast to women with isolated hypogonadotropic
hypogonadism who were reported to have fertility treat-
ment outcomes similar to that in the general population
(14), this was not the case in women with various de-
grees of hypopituitarism. In a series of 19 patients,
pregnancy was achieved in only 47%, with a live birth
rate of 6.7% per cycle (15). Although GH administra-
tion in the context of fertility treatment has been shown
to be beneficial in hypopituitary patients, pregnancy
rates were not affected by the use of GH in this series.
Another small case study reported poor pregnancy out-
comes in hypopituitary patients: live birth rate was
61%, with 50% of the babies being small for gestation-
al age or with birth weights below the 10th centile (16).
A review of 31 published cases of pregnancies in
women with hypopituitarism found similarly increased
rates of babies small for gestational age in comparison
with pregnancy controls (38 vs 12.7%), and a high in-
cidence of transverse lie (15 vs 2.1%) (17). It has been
hypothesized that uterine size may be a determinant of
poor uterine function, and that poor preparation of the
uterus prior to conception may have contributed to the
poor pregnancy outcomes, emphasizing the need for
treatment optimization.
Adulthood
Most of the knowledge concerning the effects of hor-
mone replacement therapy (HRT) originates from large
studies performed in post-menopausal women. The
expectations that HRT therapy would reduce cardio-
vascular disease, as has been suggested from epi-
demiological studies and from the established benefi-
cial effects of estrogens on the vasculature and lipid
profile (18), were shattered by the results of the
Women’s Health Initiative studies (WHI) (19). As it has
been widely publicized, treatment not only failed to pre-
vent vascular outcomes, but was associated with an in-
creased risk for stroke and ischemic heart disease. As
a consequence, the use of HRT has substantially de-
creased in all age groups, despite the fact that the av-
erage age of participants in the WHI was 63 years. Ac-
cording to data from the National Health and Nutrition
Examination Survery (NHANES), 2.5% of women aged
40-49 reported current use of oral postmenopausal
hormones in the period or 2009-2010, compared to
12.3% during 1999-2000 (20). Extrapolation of results
obtained from treatment of women in late menopause
to young hypogonadal women may be misleading and
much caution should be exercised (21). It cannot be
assumed that estrogen depletion and replacement
thereof would have similar consequences in young
women, whose endogenous estrogen levels should be
significantly higher than those obtained with standard
HRT, and in older women in whom a low estrogen mi-
lieu is physiologic. Furthermore, morbidity may vary
according to the age of onset of estrogen deficiency in
the young and its etiology (hypogonadotropic hypogo-
nadism vs primary hypogonadism due to Turner’s syn-
drome, primary ovarian insufficiency, bilateral oopho -
rectomy or following cancer therapy). Although most
data is derived from women who underwent surgical
menopause (oophorectomy), it appears that, regard-
less of the etiology, these women are at increased risk
for osteoporosis and fractures, cognitive impairment,
sexual dysfunction and cardiovascular morbidity and
mortality (22).  
That estrogen is critical for normal bone accrual, main-
tenance of bone mass and fracture prevention is indis-
putable. Its salutary effects have been well document-
ed both in young hypogonadal patients (23) and during
the post-menopausal period (19). On the other hand,
the effects of estrogen treatment on the cognitive (24)
and cardiovascular domains are controversial and
seem to be age dependent. 
For example, three large cohort studies encompassing
more than 50,000 women (the Mayo Clinic Cohort
Study of Oophorectomy and Aging, the Danish Nurse
Cohort Study, and the Nurse’s Health Study cohort)
consistently showed increased risk of ischemic heart
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disease and cardiovascular mortality among women
who underwent bilateral oophorectomy before the age
of 45 (22). Women who underwent spontaneous pre-
mature menopause before the age of 40, were also at
increased risk for ischemic heart disease. In contrast to
the detrimental effects found in the WHI study, estro-
gen therapy, particularly when instituted closely after
oophorectomy provided significant cardioprotection
(25). Hence, timing of treatment emerges as an impor-
tant factor in determining the therapeutic effect of es-
trogen replacement. There is consensus that hormone
replacement therapy for women with early onset hy-
pogonadism should be continued until the mean age of
physiological menopause (~ 51) (26).
Estrogen preparations and route of administration
Despite the fact that estrogen deficiency from different
etiologies is not rare before the mean menopausal age,
there has been no dedicated research to determine the
best hormone replacement regimen for these women,
and no specific guidelines exist. This is particularly
striking in view of the prolonged time that these patients
are exposed to treatment regimens that may have long
term health consequences. Low estrogen doses recom-
mended for postmenopausal women may not be ade-
quate for younger women, but this has not been formal-
ly studied. The Turner Syndrome Study Group recom-
mends doses equivalent to 2-4 mg of micronized estra-
diol until the age of 30 ys, subsequently reducing it to
the lowest estrogen dose for the prevention of osteo-
porosis, although no reference is given for this recom-
mendation (4). No similar age related dose breakdown
has been indicated for early onset hypogonadotropic
hypogonadism or premature ovarian insufficiency, and
it is essentially unknown if dose adjustments are re-
quired throughout the adult fertile life. As already previ-
ously mentioned, treatment should resemble as much
as possible age-appropriate physiology, which can be
mainly achieved by the use of transdermal estradiol and
natural progesterone. Although ethinyl-estradiol  con-
taining oral contraceptives are supra-physiological and
have been associated with an increase incidence of ve-
nous thromboembolic events as well as with an in-
crease risk of stroke and myocardial infarction (27),
young women may find their use more convenient or
age-appropriate. As no data is available as to the supe-
riority of oral estradiol based HRT regarding venous or
arterial thromboembolic events, it seems that emphasis
should be given to compliance with estrogen supple-
mentation, even if deemed less physiologic, taking into
consideration the well established complications of es-
trogen deprivation, mainly to the skeleton.
Oral administration of estradiol leads to pharmacologic
concentration of the hormone in the portal vein before
it is metabolized by the liver. This first-pass effect re-
sults in increased hepatic production of several hor-
mone binding globulins, clotting factors, lipoproteins
and angiotensinogen, effects that are circumvented by
transdermal administration of estrogen and have sig-
nificant clinical implications. Data from post-meno-
pausal women indicates that oral but not transdermal
estrogen was associated with an increased odds ratio
(OR 4.2 ,95% CI, 1.5 to 11.6) for venous thromboem-
bolism (VTE) (28). Oral estrogen administration, com-
pared to the transdermal route caused detrimental
changes in body composition, characterized by re-
duced lipid oxidation leading to increased fat mass,and
reduced IGF-1 levels contributing to a reduction in lean
body mass (29). A recent study performed in young
women (19-39 ys) with premature ovarian failure
showed additional beneficial effects of transdermal es-
trogen in that it caused significantly lower mean 24-
hour systolic (-7.3 mmHg) and diastolic (-7.4 mm Hg)
blood pressures compared to oral contraceptives after
12 months (30).
Progesterone preparations
Women with an intact uterus require cyclic or continu-
ous progestin administration to prevent endometrial
hyperplasia and cancer. In the WHI study, HRT con-
taining medroxyprogesterone acetate was associated
with a higher absolute risk for adverse events, mainly
related to increased cardiovascular disease and breast
cancer, in comparison to the use of estrogen alone.
The impact of different types of progesterone on VTE
risk has been recently investigated in the case-control
ESTHER study (28). There was no significant associa-
tion of VTE with micronized progesterone (OR, 0.7;
95% CI, 0.3 to 1.9) and pregnane derivatives including
dydrogesterone, medrogestone, chlormadinone ac-
etate, cyproterone acetate, and medroxyprogesterone
acetate (OR, 0.9; 95% CI, 0.4 to 2.3). In contrast, nor-
pregnane derivatives (nomegestrol acetate or
promegestone) were associated with a 4-fold-in-
creased VTE risk (OR, 3.9; 95% CI, 1.5 to 10.0) (28).
Based on this data, hormone replacement therapy
based on transdermal estradiol and micronized prog-
esterone seem to be the most physiologic regimen with
the best safety profile, particularly in women with risk
factors for VTE (31).
Patients with growth hormone deficiency
Estrogen administration reduces circulating IGF-1 lev-
els through inhibition of growth hormone receptor sig-
naling (32). This effect varies with the type and route of
estrogen administration, being more pronounced with
oral preparations that result in liver exposure to high
estradiol concentrations in the portal circulation (33).
Another consequence of this first pass effect is an in-
crease in growth hormone binding protein, thus modu-
lating growth hormone binding to its receptor. Oral
ethinyl estradiol, a potent synthetic estrogen present in
oral contraceptives, has a greater inhibitory effect on
IGF-1 levels in comparison to natural preparations
such as conjugated equine estrogen and 17β estradiol
(34). On the other hand, transdermal estradiol does not
affect IGF-1 levels, unless very high doses are used. In
addition to reducing IGF-1 levels through its direct ef-
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fect on growth hormone signaling, estrogen given per
os increases IGFBP-1 levels thus further reducing GH
metabolic actions (35).There are several clinical impli-
cations from the use of oral estrogens and in particular
ethinyl estradiol, instead of transdermal estrogen, when
concurrently treating GH-deficient patients: 1) signifi-
cantly higher doses of recombinant GH are needed to
achieve similar or even lower IGF-1 levels, thus signifi-
cantly increasing costs (34); 2) the beneficial metabolic
effects of GH treatment on lipid oxidation and protein
synthesis are attenuated, thus compromising the ex-
pected positive effects on body composition (36). 
Despite evidence of the advantages of transdermal es-
trogen therapy in GH-deficient/treated patients, over
80% of these young women receive oral estrogen re-
placement therapy, including a high percentage of oral
contraceptives use (37). 
Conclusions
There is accumulating evidence indicating greater
safety and superior clinical outcomes when estradiol is
administered using the transdermal route, spanning
puberty and the fertile adult age. Transdermal estradi-
ol should be preferentially used particularly in women
with concurrent growth hormone deficiency.
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